381 related articles for article (PubMed ID: 27988420)
1. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
3. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.
Cook DA; Smith LW; Law JH; Mei W; Gondara L; van Niekerk DJ; Ceballos KM; Jang D; Chernesky M; Franco EL; Ogilvie GS; Coldman AJ; Krajden M
J Clin Virol; 2018 Nov; 108():32-37. PubMed ID: 30223252
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
[TBL] [Abstract][Full Text] [Related]
7. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
[TBL] [Abstract][Full Text] [Related]
8. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology.
Castle PE; Eaton B; Reid J; Getman D; Dockter J
J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M
BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
11. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
13. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
16. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
Cuschieri K; Cubie H; Graham C; Rowan J; Hardie A; Horne A; Earle CB; Bailey A; Crosbie EJ; Kitchener H
J Clin Virol; 2014 Feb; 59(2):104-8. PubMed ID: 24380720
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study.
Reid JL; Wright TC; Stoler MH; Cuzick J; Castle PE; Dockter J; Getman D; Giachetti C
Am J Clin Pathol; 2015 Sep; 144(3):473-83. PubMed ID: 26276778
[TBL] [Abstract][Full Text] [Related]
19. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.
Kelly HA; Chikandiwa A; Sawadogo B; Gilham C; Michelow P; Lompo OG; Omar T; Zan S; Magooa P; Segondy M; Nagot N; Meda N; Delany-Moretlwe S; Mayaud P;
PLoS Med; 2021 Mar; 18(3):e1003528. PubMed ID: 33661957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]